Xushen Xiong

Xushen Xiong

Auto-generated profile, based on publicly available information

Xushen Xiong

The Second Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Cell
Verified
Journal Article
Open access
XXXushen Xiong
Xushen Xiong
BJBenjamin T. James
Benjamin T. James
CBCarles A. Boix
Carles A. Boix
YPYongjin P. Park
Yongjin P. Park
KGKyriaki Galani
Kyriaki Galani
MKManolis Kellis
Manolis Kellis
Recent work has identified dozens of non-coding loci for Alzheimer's disease (AD) risk, but their mechanisms and AD transcriptional regulatory circuitry are poorly understood. Here, we profile epigenomic and transcriptomic landscapes of 850,000 nuclei from prefrontal cortexes of 92 individuals with and without AD to build a map of the brain regulome, including epigenomic profiles, transcriptional regulators, co-accessibility modules, and peak-to-gene links in a cell-type-specific manner. We develop methods for multimodal integration and detecting regulatory modules using peak-to-gene linking. We show AD risk loci are enriched in microglial enhancers and for specific TFs including SPI1, ELF2, and RUNX1. We detect 9,628 cell-type-specific ATAC-QTL loci, which we integrate alongside peak-to-gene links to prioritize AD variant regulatory circuits. We report differential accessibility of regulatory modules in late AD in glia and in early AD in neurons. Strikingly, late-stage AD brains show global epigenome dysregulation indicative of epigenome erosion and cell identity loss.

28 September 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LHLei Hou
Lei Hou
XXXushen Xiong
Xushen Xiong
YPYongjin Park
Yongjin Park
CBCarles Boix
Carles Boix
BJBenjamin James
Benjamin James
MKManolis Kellis
Manolis Kellis
Genetic variants associated with complex traits are primarily noncoding, and their effects on gene-regulatory activity remain largely uncharacterized. To address this, we profile epigenomic variation of histone mark H3K27ac across 387 brain, heart, muscle and lung samples from Genotype-Tissue Expression (GTEx). We annotate 282 k active regulatory elements (AREs) with tissue-specific activity patterns. We identify 2,436 sex-biased AREs and 5,397 genetically influenced AREs associated with 130 k genetic variants (haQTLs) across tissues. We integrate genetic and epigenomic variation to provide mechanistic insights for disease-associated loci from 55 genome-wide association studies (GWAS), by revealing candidate tissues of action, driver SNPs and impacted AREs. Lastly, we build ARE–gene linking scores based on genetics (gLink scores) and demonstrate their unique ability to prioritize SNP–ARE–gene circuits. Overall, our epigenomic datasets, computational integration and mechanistic predictions provide valuable resources and important insights for understanding the molecular basis of human diseases/traits such as schizophrenia.

19 May 2017 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
XXXushen Xiong
Xushen Xiong
CYChengqi Yi
Chengqi Yi
JPJinying Peng
Jinying Peng

15 May 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
TMTian-Zhu Ma
Tian-Zhu Ma
LLLiu-Yi Liu
Liu-Yi Liu
YZYou-Liang Zeng
You-Liang Zeng
KDKe Ding
Ke Ding
HZHang Zhang
Hang Zhang
ZMZong-Wan Mao
Zong-Wan Mao
G-quadruplexes (G4s) are atypical nucleic acid structures involved in basic human biological processes and are regulated by small molecules. To date, pyridostatin and its derivatives [e.g., PyPDS (4-(2-aminoethoxy)-N2,N6-bis(4-(2-(pyrrolidin-1-yl) ethoxy) quinolin-2-yl) pyridine-2,6-dicarboxamide)] are the most widely used G4-binding small molecules and considered to have the best G4 specificity, which provides a new option for the development of cisplatin-binding DNA. By combining PyPDS with cisplatin and its analogs, we synthesize three platinum complexes, named PyPDSplatins. We found that cisplatin with PyPDS (CP) exhibits stronger specificity for covalent binding to G4 domains even in the presence of large amounts of dsDNA compared with PyPDS either extracellularly or intracellularly. Multiomics analysis reveals that CP can effectively regulate G4 functions, directly damage G4 structures, activate multiple antitumor signaling pathways, including the typical cGAS-STING pathway and AIM2-ASC pathway, trigger a strong immune response and lead to potent antitumor effects. These findings reflect that cisplatin-conjugated specific G4 targeting groups have antitumor mechanisms different from those of classic cisplatin and provide new strategies for the antitumor immunity of metals.

27 March 2025 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
GLGuohua Li
Guohua Li
CNCheng Ni
Cheng Ni
JWJiacheng Wang
Jiacheng Wang
FZFeimu Zhang
Feimu Zhang
ZFZaiyang Fu
Zaiyang Fu
XHXinyang Hu
Xinyang Hu

29 May 2024 in Advanced Science
Verified
Journal Article
Open access
GWGang Wang
Gang Wang
HWHangdi Wu
Hangdi Wu
XZXiuwen Zhai
Xiuwen Zhai
LZLi Zhang
Li Zhang
CZChangming Zhang
Changming Zhang
ZLZhihong Liu
Zhihong Liu
Wilms tumor‐1(WT1) is a crucial transcription factor that regulates podocyte development. However, the epigenomic mechanism underlying the function of WT1 during podocyte development has yet to be fully elucidated. Here, single‐cell chromatin accessibility and gene expression maps of foetal kidneys and kidney organoids are generated. Functional implications of WT1‐targeted genes, which are crucial for the development of podocytes and the maintenance of their structure, including BMPER/PAX2/MAGI2 that regulates WNT signaling pathway, MYH9 that maintains actin filament organization and NPHS1 that modulates cell junction assembly are identified. To further illustrate the functional importance of WT1‐mediated transcriptional regulation during podocyte development, cultured and implanted patient‐derived kidney organoids derived from the Induced Pluripotent Stem Cell (iPSCs) of a patient with a heterozygous missense mutation in WT1 are generated. Results from single‐cell RNA sequencing (scRNA‐seq) and functional assays confirm that the WT1 mutation leads to delays in podocyte development and causes damage to cell structures, due to its failure to activate the targeting genes MAGI2, MYH9, and NPHS1. Notably, correcting the mutation in the patient iPSCs using CRISPR‐Cas9 gene editing rescues the podocyte phenotype. Collectively, this work elucidates the WT1‐related epigenomic landscape with respect to human podocyte development and identifies the disease‐causing role of a WT1 mutation.